It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Cutaneous malignant melanoma is an aggressive cancer of melanocytes with a strong propensity to metastasize. We posit that melanoma cells acquire metastatic capability by adopting an embryonic-like phenotype, and that a lineage approach would uncover metastatic melanoma biology. Using a genetically engineered mouse model to generate a rich melanoblast transcriptome dataset, we identify melanoblast-specific genes whose expression contribute to metastatic competence and derive a 43-gene signature that predicts patient survival. We identify a melanoblast gene, KDELR3, whose loss impairs experimental metastasis. In contrast, KDELR1 deficiency enhances metastasis, providing the first example of different disease etiologies within the KDELR-family of retrograde transporters. We show that KDELR3 regulates the metastasis suppressor, KAI1, and report an interaction with the E3 ubiquitin-protein ligase gp78, a regulator of KAI1 degradation. Our work demonstrates that the melanoblast transcriptome can be mined to uncover targetable pathways for melanoma therapy.
Metastatic cells can mimic many of the phenotypic behaviors of embryonic cells. Here, the authors generate a melanoblast-specific transcriptome using a genetically engineered mouse model and identify KDELR3 as a pro-metastasis gene in melanoma.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 National Institutes of Health, Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165)
2 National Institutes of Health, Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165); Johns Hopkins Medical Institutions, Department of Otolaryngology—Head and Neck Surgery, Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)
3 National Cancer Institute, Laboratory of Protein Dynamics and Signaling, Center for Cancer Research, Frederick, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075)
4 National Institutes of Health, Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165)
5 Lewis Katz School of Medicine at Temple University, Fels Institute for Cancer Research and Molecular Biology, Philadelphia, USA (GRID:grid.264727.2) (ISNI:0000 0001 2248 3398)
6 National Institutes of Health, Experimental Pathology Laboratory, Center for Cancer Research, National Cancer Institute, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165)
7 Leidos Biomedical Research Inc., Small Animal Imaging Program, Frederick National Laboratory for Cancer Research, Frederick, USA (GRID:grid.419407.f) (ISNI:0000 0004 4665 8158)
8 National Institute of Health, Mammalian Development Section, National Institute of Neurological Disorders and Stroke, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165)
9 National Institutes of Health, Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165)
10 National Institutes of Health, Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165); Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943)